AbbVie Q3 Results: Revenue beats estimates at $17.404 billion
AbbVie reported Q3 revenue of $17.404B, beating estimates. EPS was $3.82, also exceeding expectations. Shares fell 2.03% to $288.91. Analysts raised price targets, citing strong performance and future growth prospects, but noted mixed drug performance. The company is diversifying its immunology business.
How this was made
The 30-second read
Why it matters
The key trading tension is between headline outperformance and franchise-level nuance. Raised price targets suggest confidence in longer-duration momentum, while the stock’s drop implies investors are demanding stronger drug-specific execution.
Market read
This is a post-earnings decision point for ABBV positioning, balancing a headline beat against perceived softness in specific franchise performances.
What to watch
The article highlights “less impressive” beats in Skyrizi and Rinvoq; traders may be underweighting how that could affect near-term guidance, channel inventory, or payer dynamics despite the overall revenue/EPS outperformance.
Background
AbbVie’s Q3 results beat consensus on revenue and EPS, but the stock declined in early trading as analysts and the market debated the quality of the beat across key immunology drugs.
Ticker impact
AbbVie reported Q3 revenue of $17.404B and EPS $3.82, beating consensus, while shares fell 2.03% and analysts raised targets citing franchise momentum.
Likely choppy trading, with near-term pressure from the stock’s post-earnings drop offset by analyst target hikes tied to Immunology and Neuroscience momentum.
The article pairs a clear beat (revenue and EPS) with a same-session negative reaction and notes weaker-than-expected performance in Skyrizi and Rinvoq, while also citing potential reacceleration from subcutaneous Skyrizi approval and raised targets.
Market effects
Signals that investors in large-cap pharma are scrutinizing franchise drug-level performance even when top-line and EPS beat.
No specific regional market linkage beyond US premarket/early-session reaction.
Limited, primarily impacts US-listed pharma sentiment around immunology franchise durability.
Counterpoint
The negative reaction may be overdone if the AFFIRM-driven subcutaneous Skyrizi approval meaningfully improves uptake, making the beat a precursor to stronger Q4/2027 momentum.
Key entities
- companyAbbVie
Reported Q3 revenue $17.404B and EPS $3.82, with shares down 2.03% early Monday; analysts raised targets citing Immunology and Neuroscience momentum and subcutaneous Skyrizi approval context.
- brokerageGuggenheim Securities
Maintained Buy rating and raised target from $288 to $322, citing franchise momentum expectations.
- brokerageCantor Fitzgerald
Maintained Overweight rating and raised target from $290 to $325, noting the beat came against lowered expectations and pointing to potential reacceleration from subcutaneous Skyrizi approval.
